Back to Journals » OncoTargets and Therapy » Volume 11

Research progress on GP73 in malignant tumors

Authors Liang R, Liu Z, Piao X, Zuo M, Zhang J, Liu Z, Li Y, Lin Y

Received 24 July 2018

Accepted for publication 25 September 2018

Published 24 October 2018 Volume 2018:11 Pages 7417—7421

DOI https://doi.org/10.2147/OTT.S181239

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Dr Leo Jen-Liang Su


Rong Liang, Ziyu Liu, Xuemin Piao, Mingtang Zuo, Jinyan Zhang, Zhihui Liu, Yongqiang Li, Yan Lin

Department of Medical Oncology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi 530021, People’s Republic of China

Abstract: Malignant cancer is one of the most serious diseases that currently endanger human health. As most tumors are diagnosed at an advanced stage, the current treatments show poor therapeutic efficacy, and the patients have poor prognosis. However, a 5-year survival rate higher than 80% could be achieved if tumors are diagnosed at an early stage. Therefore, early diagnosis and treatment play important roles in the prevention and treatment of malignant tumors, and serum tumor markers are important for the early diagnosis of malignant cancers. Recent studies have shown that GP73, a transmembrane protein, has greater diagnostic value in primary liver cancer than in other types of cancers, and research on the regulation of GP73 expression has unveiled broad prospects in anticancer targeted therapy. Thus, GP73, as a new tumor marker, deserves further study.

Keywords: GP73, malignant tumors, tumor marker, diagnosis, prognosis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]